Global Infertility Drugs Market Size study & Forecast, by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Other Drug Classes), End User (Male and Female), Distribution Channel (Hospital Pha

Global Infertility Drugs Market Size study & Forecast, by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Other Drug Classes), End User (Male and Female), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Regional Analysis, 2022-2029

Global Infertility Drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. The term infertility medicines refers to a group of pharmaceuticals that are used to treat infertility and improve a person's reproductive health. They can be swallowed or administered intravenously. Gonadotrophins, dopamine agonists, aromatase inhibitors, biguanides, ovulatory stimulants, selective oestrogen receptor modulators (SERMs), and tricyclic antidepressants are a few of the medications that are frequently used to treat infertility. The infertility drugs market is anticipated to expand significantly owing to upsurge in Healthcare Awareness along with increasing aging female population and growing prevalence of stress and life-style disorders among men and women.

The National Center for Drug Abuse Statistics found that during the COVID-19 lockdowns, almost 60.0% of Americans increased their alcohol intake. In a similar vein, according to a study issued by the World Health Organization in 2021, China had more than 300.0 million smokers, or over one-third of the world's population at the time. In China, there were around 26.6% of adults who smoked who were 15 years of age or older. One of the major contributors to hormonal imbalance, polycystic ovarian disease, and weight problems, which have an immediate influence on the embryo and might cause infertility concerns, is a healthy lifestyle. On the other side, over the past 16 years, the percentage of males with a normal total motile sperm count has decreased by around 10%. The evidence is clear: Men today generate less and less healthy sperm than in the past. However, strict regulatory structure that impedes the approval of products stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Infertility Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to menopausal disorders and high concentration of market players or manufacturer's presence. However, Asia Pacific expected to be the fastest growing region owing to rising healthcare expenditures and initiatives by the government to increase the availability of the infertility treatment in the developing nations.

Major market player included in this report are:
Abbott Laboratories
Ferring Pharmaceuticals Inc.
Merck KGaA
Pfizer Inc.
Novartis International AG
Bayer AG
Theramex
Mankind Pharma
Teva Pharmaceuticals Industries
Livzon

Recent Developments in the Market:

In order to sell Genea Biomedx's (Australia) fertility products in the US and Canada, Genea Biomedx (Australia) partnered with Hamilton Thorne in 2020.

In August 2021, Merck introduced Pergoveris Pen in India for the treatment of infertility. The Pergoveris Pen is the first item to ever include both recombinant follicle-stimulating hormone and recombinant luteinizing hormone in a ready-to-use, IVF specialist-prescribed device. A pen with bulk technology that has received international approval offers infertile couples a more secure self-service infertility option.
Global Infertility Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage
Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered
Drug class, End User, Distribution Channel, Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope
Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below.
By Drug Class:
Gonadotrophins
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Other Drug Classes
By End User:
Male
Female
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australi.
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Abbott Laboratories
Ferring Pharmaceuticals Inc.
Merck KGaA
Pfizer Inc.
Novartis International AG
Bayer AG
Theramex
Mankind Pharma
Teva Pharmaceuticals Industries
Livzon

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.